Department of Medicine, Division of Haematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
Platelets. 2011;22(1):1-7. doi: 10.3109/09537104.2010.515697. Epub 2010 Oct 22.
Splenectomy is the usual form of therapy for immune thrombocytopena (ITP) after steroid failure. We retrospectively studied the data in adult patients who underwent splenectomy for ITP from July 1996 to June 2008 to evaluate the long term responses, clinical and laboratory factors associated with long term responses and outcome of relapsed or refractory patients. Thirty eight patients, 30 (79%) females, with a median age of 23 years (range 15-69), underwent splenectomy. The procedure was laparoscopic in 28 (73.5%) and open in 10 patients. Splenectomy resulted in a response in 34/38 (89.5%) patients and failed in four (10.5%) patients. After a median follow-up of 58 months (range 7-144), 24 (63%) patients had a maintained response without treatment (platelet count of >50 × 10⁹)/l). Most of the relapses occurred during the first year but two patients had late relapses. There were procedure-related complications in seven (18.0%) patients but no cases of overwhelming sepsis. Only four relapsed or refractory patients had a platelet count below 50 × 10⁹/l at the last follow-up indicating response to alternative therapies. Responsiveness to steroids before the procedure (p = 0.025) along with a platelet count of ≥ 150 × 10⁹/l at 4 weeks (p = < 0.0001) and a highest platelet count of ≥ 400 × 10⁹/l at any time post-splenectomy (p = 0.005), were associated with a long term response in univariate analysis. In conclusion, splenectomy remains an effective treatment for ITP after steroid failure in terms of long term responses, and the majority of relapsed or refractory patients respond to alternative therapies.
脾切除术是激素治疗失败后免疫性血小板减少症(ITP)的常用治疗方法。我们回顾性研究了 1996 年 7 月至 2008 年 6 月期间因 ITP 而行脾切除术的成年患者的数据,以评估长期反应、与长期反应相关的临床和实验室因素以及复发或难治性患者的结局。38 例患者,30 例(79%)为女性,中位年龄 23 岁(范围 15-69 岁),行脾切除术。28 例(73.5%)为腹腔镜手术,10 例为开放性手术。脾切除术后 34/38 例(89.5%)患者有效,4 例(10.5%)患者无效。中位随访 58 个月(范围 7-144 个月)后,24 例(63%)患者未治疗时血小板计数持续升高(>50×10⁹)/l)。大多数复发发生在第一年,但有 2 例患者发生迟发性复发。7 例(18.0%)患者出现与手术相关的并发症,但无败血症病例。只有 4 例复发或难治性患者在最后一次随访时血小板计数<50×10⁹/l,表明对替代治疗有反应。术前对激素的反应性(p=0.025)、术后 4 周血小板计数≥150×10⁹/l(p<0.0001)和脾切除术后任何时间血小板计数≥400×10⁹/l(p=0.005)与单因素分析中的长期反应相关。总之,脾切除术在激素治疗失败后仍是 ITP 的有效治疗方法,大多数复发或难治性患者对替代治疗有反应。